SOPHiA GENETICS is excited to be a part of the Precision Medicine World Conference 2022 annual meeting, held in-person in Silicon Valley, CA from January 26th–28th.
You will have the chance to chat with our experts at our booth #D2520 and schedule a demo of the universal SOPHiA DDM™ platform. Check out our agenda below to stay up to date on our SCOPE presence!
Track 7 - Showcase
January 26th at 11am PST
Speaker: TBA, SOPHiA GENETICS
Our vision lies in leveraging our capabilities and decentralized approach to identify biomarkers, refine disorders stratification, and pioneer multimodal predictive analytics. Collaborating with the biopharma community, we establish partnerships to derive insights that could have transformative potential for advancing drug research and development.
Track 2 – AI & Data Sciences
January 27th at 3:30pm PST
Speaker: Philippe Menu, MD-PhD, MBA – Chief Medical Officer, SOPHiA GENETICS
Thanks to new technologies and computing capacities, multimodality holds the potential to increase precision in diagnosis, prognosis and treatment decisions. Dr. Menu will apply this to a large-scale multi-centric study where the deep-learnings analysis of the aggregation of multimodal data (clinical, biological, genomic, and radiomics data) is used to identify predictive signatures associated with response to treatment and prognosis of patients with stage IV non-small cell lung cancer.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.